Back to Search
Start Over
Efficacy and Safety of Bortezomib in the Treatment of Active Antibody-Mediated Rejection in Adult Kidney-Transplant Recipients: A Single-Center Retrospective Study.
- Source :
- Indian Journal of Transplantation; Jan-Mar2022, Vol. 16 Issue 1, p101-106, 6p
- Publication Year :
- 2022
-
Abstract
- Introduction: The management of active antibody-mediated rejection (ABMR) is evolving, and optimal treatment remains uncertain due to incomplete understanding of pathogenesis. Bortezomib is found to be useful in the treatment of active ABMR. We studied the efficacy and safety of bortezomib in renal-transplant recipients with active ABMR. Materials and Methods: We retrospectively included renal-transplant recipients with active ABMR, who received bortezomib as main management. Results: Eighteen live-related renal-transplant recipients of active ABMR were included. C4d was positive in 14 patients and negative in eight patients. Patients with active ABMR had a mean improvement in glomerular filtration rate (GFR) of 7, 10.5, and 15 ml/min/1.73 m2 at 3, 6, and 12 months, respectively, from baseline GFR. Improvement was significant at 3 (P = 0.009) and 6 months (P = 0.018) of follow-up. Conclusion: Bortezomib may be a safe and effective therapy in patients with active ABMR in patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- DRUG efficacy
GLOMERULAR filtration rate
GRAFT rejection
PROTEASE inhibitors
ACQUISITION of data methodology
ANALYSIS of variance
RESEARCH methodology
KIDNEY transplantation
RETROSPECTIVE studies
MEDICAL records
DESCRIPTIVE statistics
REPEATED measures design
PLASMAPHERESIS
DATA analysis software
TRANSPLANTATION of organs, tissues, etc.
EVALUATION
ADULTS
Subjects
Details
- Language :
- English
- ISSN :
- 22120017
- Volume :
- 16
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Indian Journal of Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 156116673
- Full Text :
- https://doi.org/10.4103/ijot.ijot_155_20